TKI resistance in CML is primarily caused by the re-establishment of hyperactive ABL kinase either through acquired mutations in the BCR/ABL kinase domain or its gene amplification [9–11]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.